Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tadekinig alfa - AB2 Bio

Next Previous
Drug Profile

Tadekinig alfa - AB2 Bio

Alternative Names: IL-18BP - AB2 Bio; r-hIL-18BP; Recombinant human IL-18 binding protein - AB2 Bio

Latest Information Update: 16 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AB2 Bio
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 1 inhibitors; Interleukin 18 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophagocytic lymphohistiocytosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Immunological disorders
  • Phase II Adult-onset Still's disease

Most Recent Events

  • 02 Nov 2023 AB2 Bio completes phase-III trials in Immunological disorders (In adolescents, In children) in USA, Canada, Germany (SC) (NCT03113760)
  • 07 Mar 2023 AB2 Bio plans to submit marketing authorization application
  • 07 Mar 2023 AB2 Bio completes enrolment in its Phase-III clinical trials in Immunological disorders (In adolescents, In children) in USA, Canada, Germany (SC) (NCT03113760)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top